Diagnostic value of galectin-3 and hector battifora mesothelial epitope (hbme)-1 as a marker for malignancy in the diagnosis of thyroid lesions

Durry, Meilany F.; Miskad, Upik Anderiani; Leiwakabessy, Winny Natacia; Cangara, Muhammad Husni

doi:10.1016/j.pathol.2015.12.325

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Galectin-3 and HBME-1 may be used as single discriminators between follicular thyroid adenoma and carcinoma. Significant differences in galectin-3 and HBME-1 were identified between benign and malignant lesions, and also between the subgroups of benign and malignant lesions ( 127 – 130 ). Galectin-3 and HBME-1 have an excellent sensitivity and specificity for malignant thyroid lesions (100 and 89.1%, respectively) ( 129 ).…”

Section: Galectin-3 and Cancermentioning

confidence: 93%

“…Galectin-3 is also used in combination with other biomarkers for a differential diagnosis of thyroid lesions. The most commonly combined biomarkers are Hector Battifora mesothelial epitope-1 (HBME-1) and cytokeratin-19 ( 127 – 130 ). Galectin-3 and HBME-1 may be used as single discriminators between follicular thyroid adenoma and carcinoma.…”

Section: Galectin-3 and Cancermentioning

confidence: 99%

“…Galectin-3 and HBME-1 have an excellent sensitivity and specificity for malignant thyroid lesions (100 and 89.1%, respectively) ( 129 ). Despite core needle biopsies leading to the diagnosis of the majority of thyroid nodules, the accuracy is increased by also observing the galectin-3, cytokeratin-19 and HBME-1 panels, indicating their additional diagnostic value when combined with routine histology ( 127 – 130 ). It was also reported that galectin 3, cluster of differentiation (CD)44 and, to an extent, HBME-1, are useful immunocytochemical parameters with the potential to support the fine needle aspiration cytology diagnosis of PTC, particularly in situations where the differential diagnoses is complicated ( 131 ).…”

Section: Galectin-3 and Cancermentioning

confidence: 99%

See 2 more Smart Citations

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

Galectin-3 is a member of the galectin family, which are β-galactoside-binding lectins with ≥1 evolutionary conserved carbohydrate-recognition domain. It binds proteins in a carbohydrate-dependent and -independent manner. Galectin-3 is predominantly located in the cytoplasm; however, it shuttles into the nucleus and is secreted onto the cell surface and into biological fluids including serum and urine. It serves important functions in numerous biological activities including cell growth, apoptosis, pre-mRNA splicing, differentiation, transformation, angiogenesis, inflammation, fibrosis and host defense. Numerous previous studies have indicated that galectin-3 may be used as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease and cancer. With emerging evidence to support the function and application of galectin-3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin-3 in associated diseases.

show abstract

Section: Galectin-3 and Cancermentioning

confidence: 93%

Section: Galectin-3 and Cancermentioning

confidence: 99%

Section: Galectin-3 and Cancermentioning

confidence: 99%

See 1 more Smart Citation

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Galectin-3 is also used in combination with other biomarkers for a differential diagnosis of thyroid lesions. The most commonly combined biomarkers are Hector Battifora mesothelial epitope-1 (HBME-1) and cytokeratin-19 [24][25][26][27]. However galectin-3 may not be used as single discriminators between follicular thyroid adenoma and carcinoma [24][25][26][27].…”

Section: Discussionmentioning

confidence: 99%

“…The most commonly combined biomarkers are Hector Battifora mesothelial epitope-1 (HBME-1) and cytokeratin-19 [24][25][26][27]. However galectin-3 may not be used as single discriminators between follicular thyroid adenoma and carcinoma [24][25][26][27]. Some studies show that galectin-3 and HBME-1 have an excellent sensitivity and specificity for malignant thyroid lesions (100 and 89.1%, respectively) [26].…”

Section: Discussionmentioning

confidence: 99%

Does Galectin3 Immunohistochemical Marker Help in Diagnosing the Nature of Benign or Malignant Thyroid Tumor?

Farwa

Ramzan

Niaz

et al. 2021

JAMMR

View full text Add to dashboard Cite

Introduction: Galectin-3 has been reported quite accurate to detect or exclude malignancy in nodules with prior indeterminate Fine Needle Aspiration Cytology and per operative findings. Keeping this fact in mind, Galectin-3 can have a pivotal role in separating benign from the malignant thyroid neoplasms. We aim to determine the frequency and intensity of Galectin-3 immunohistochemical expression among benign and malignant thyroid neoplasms confirmed on histopathology. Materials and Methods: We studied 78 thyroid specimens diagnosed with thyroid neoplasms on histopathology. Out of these 39 were benign cases (follicular adenoma and hurthle cell adenoma) and 39 were malignant cases (papillary thyroid carcinomas, follicular carcinoma, medullary carcinoma and poorly differentiated carcinoma). Each specimen was examined grossly and microscopically and checked for immunohistochemical staining pattern of Galectin-3 under the microscope. Results: Age range in this study was from 15 to 65 years with mean age of 44.97 ± 10.78 years. Out of these 78 patients, 17 (21.79%) were male and 61 (78.21%) were female with male to female ratio of 1:3.6. Frequency of positive Galectin-3 immuno histochemical expression among thyroid neoplasms was found in 32 (41.03%) cases with Galectin-3 showing positive staining in 21 (53.85%) of all malignant and 11 (28.21%) of all benign cases .Among the malignant neoplasms, positivity was seen most frequently in papillary thyroid carcinomas as compared to the other malignancies. Conclusion: This study concluded that positive Galectin-3 immunohistochemical expression is more in malignant thyroid neoplasms (53.85%) as compare to the benign lesions (28.21%). Therefore, we recommend that this marker cannot be used alone for the routine diagnosis of malignant lesions as it has shown less sensitivity and specificity. Moreover it also has shown no significant role in differentiating between the benign and the malignant thyroid neoplasms.

show abstract

Diagnostic value of galectin-3 and hector battifora mesothelial epitope (hbme)-1 as a marker for malignancy in the diagnosis of thyroid lesions

Cited by 2 publications

References 0 publications

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Does Galectin3 Immunohistochemical Marker Help in Diagnosing the Nature of Benign or Malignant Thyroid Tumor?

Contact Info

Product

Resources

About